Bertil Lindmark

Broschiertes Buch

The Amazing Biological Revolution and The Amazing New Health Care

Beschreibung

There is a biological revolution going on around us. Every day we hear broadcasts of new findings central to disease processes. New technology and new insights keep building. But can we as individuals reap the benefits of this revolution, and can we make it accessible to the many people around the world? Can we keep the new ways to interact with our biology safe? At the same time, we see the limitations. Not enough quality knowledge is reaching us quickly enough, and disinformation is leading people astray. We are in need of rapid translation of insights into therapeutics. But surely enough, we are on a fantastic trajectory for the future if compared to the past. For several hundred years, the knowledge has been building and we have seen an accelerating pace of new insights and possible interventions, both regarding diagnostics and therapeutics. But health care is basically still organised like it was in the 1920s. The question to ask then is, what if we could turn health care on its head and instead of the passive catastrophe and angst-based current paradigm it is, turn health care into a force that allows long, disease-free lives? Professor Bertil Lindmark as a trained physician claims that this is possible. In the next 100 years, we can move to a kind of health care which nips disease in the bud, cures it preemptively, and allows us to live without worrying about the spectre of disease. In The Amazing Biological Revolution And The Amazing New Health Care, he details how we can make this possible.

Autor

Bertil Lindmark (MD, PhD) is a Swedish professor in molecular epidemiology. He has spent years studying the human biology. His work with some of the top pharmaceuticals in the world such as Astra and AstraZeneca speaks for itself. Not only that, he has played an instrumental role in developing the billion-dollar selling drug Symbicort for asthma and COPD. In Japan, he led the Clinical Development before he moved on to become the global head of R&D at Almirall in Barcelona, Spain. There he developed the second long-acting antimuscarinic to the market in the US and in EU, and several other compounds, which were acquired by AstraZeneca in 2014. He then became the Chief Medical Officer of ASLAN Pharmaceuticals in Singapore and led the development of several oncology and dermatology compounds. In 2019, he started at eTheRNA Immunotherapies in Belgium as the CMO leading the clinical development of cancer immunotherapies using similar technology as Moderna and BionTech. Since 2020, Bertil Lindmark has been serving as the CMO Galecto Biotech in Copenhagen, Denmark. His focus here is to use antagonists of galectin-3 which is a central pro-inflammatory and pro-fibrotic molecule to develop medicines against fibrosis and cancer.

Produktdetails

• Seitenzahl: 88
• Erscheinungstermin: 22. Dezember 2021
• Englisch
• Abmessung: 229mm x 152mm x 5mm
• Gewicht: 127g
• ISBN-13: 9781915206671
• ISBN-10: 1915206677
• Artikelnr.: 63515636